Technology
Health
Biotechnology
Kazia Therapeutics
$3.109876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell KZIA and other stocks, options, ETFs, and crypto commission-free!
About
Kazia Therapeutics Ltd. engages in the pharmaceutical drug development. It involves in preclinical research confirms efficacy of cantrixil which induces cell death in chemoresistant ovarian cancer stem cells. Read More The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
CEO
Employees
—
Headquarters
Sydney, New South Wales (NSW)
Founded
1994
Market Cap
19.27M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
7.11K
High Today
—
Low Today
—
Open Price
—
Volume
0.00
52 Week High
$5.59
52 Week Low
$2.04
Collections
Technology
Health
Biotechnology
Therapy
Pharmaceutical
Cancer Prevention
News
Markets InsiderMay 8
New positive data from phase IIa trial in brain cancer patients
SYDNEY, May 8, 2019 /PRNewswire/ -- With one month to go until World Brain Tumour Day on June 8, Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce new safety data from its ongoing phase IIa study of GDC-0084 in newly-diagnosed patients with glioblastoma (GBM). Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8542751-kazia-therapeutics-glioblastoma/ Licensed from Genentech in Oc...
PR NewswireMay 8
Kazia calls for greater awareness of the deadliest gynecological cancer in the US
SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA,NASDAQ: KZIA) calls for greater awareness of what is the most lethal gynaecological cancer in the US. In 2019, around 22,530 women will receive a new diagnosis of ovarian cancer[1] while the disease has one of the lowest survival rates of all female cancers, with only 46.5% of patients surviving five years post diagnosis[2]. Kazia's CEO, Dr James Garner said, "In ...
Markets InsiderMay 7
Kazia calls for greater awareness of the most lethal women's disease in Australia
SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal women's disease in Australia.
Price Paid on Robinhood
47% Lower
Right Now
52 Week Low
$2.04
52 Week High
$5.59
Average Price Paid
$5.86